Skip to main content

Table 1 Patient characteristics (N = 40)

From: First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

Patients entered and enrolled 40
Median age, years (range) 61.5 (30–76)
WHO performance status, n (%)  
   0 18 (45.0)
   1 16 (40.0)
   2 6 (15.0)
Histology, n (%)  
   Breast 1 (2.5)
   Ductal breast 31 (77.5)
   Lobular breast 8 (20.0)
Number of metastatic sites, n (%)  
   1 12 (30.0)
   2 21 (52.5)
   3 4 (10.0)
   ≥4 3 (7.5)
Metastatic sites of diseasea, n (%)  
   Visceral 35 (87.5)
   Liver 26 (65.0)
   Lung (including pleura) 17 (42.5)
   Nonvisceral only 5 (12.5)
Menopausal status, n (%)  
   Pre-menopausal 20 (50.0)
   Menopausal 8 (20.0)
   Post-menopausal 10 (25.0)
   Unknown 2 (5.0)
Estrogen/progesterone receptors, n (%)  
   Positive 23 (57.5)
   Negative 12 (30.0)
   Unknown 5 (12.5)
  1. aPatients may be counted in more than one category.